Phaseline

Targets › FECH

FECH (Ferrochelatase, mitochondrial): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2027.

Catalyzes the ferrous insertion into protoporphyrin IX and participates in the terminal step in the heme biosynthetic pathway. (UniProt, P22830)

Open in Phaseline: the race on FECH, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
David W. Roberts5-aminolevulinic acid
Prodrug that is metabolized to protoporphyrin IX (PpIX), a fluorescent porphyrin that accu
FECHPhase 1Brain TumorsDec 2027

Conditions

Brain Tumors (1)

Modalities

small molecule (1)

Companies

David W. Roberts (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.